What we do
CEPI leverages its unique position within the global health and R&D ecosystems to address market failures, building on its track record of bringing together public-sector, private-sector, and academic partners to accelerate the development of vaccines against emerging viral threats.
30+
Number of investors, from governments to philanthropies, who have donated to CEPI
Up to $3.1 bn
Committed investments in R&D&M projects since CEPI's launch
400+
Global R&D&M partners collaborating with CEPI
Priority pathogens
CEPI supports the development of vaccines, platform technologies and manufacturing innovations to combat priority pathogens for which no licensed vaccines are currently available.
Research and development
CEPI is leading a broad range of ambitious programmes that aim to substantially reduce global epidemic and pandemic risk.
Manufacturing and supply chain
CEPI is bolstering global manufacturing capacity in underserved regions and harnessing innovative technologies to improve the speed, scale and access of vaccine manufacturing in response to epidemic and pandemic threats.
Calls for Proposals
Innovators worldwide are invited to apply to our scientific programmes to advance the development and manufacture of vaccines and tools against epidemic and pandemic threats.
Our portfolio
Since our launch in 2017, CEPI has carefully selected and announced over 50 partnerships to advance vaccine candidates against our priority pathogens and platform technologies for use against Disease X.
View our portfolio
Our impact
CEPI has backed the development of 30+ vaccine candidates for its priority pathogens, overseeing scientific breakthroughs, including the first-ever approved Chikungunya vaccine, and advancing the first-ever Nipah vaccine into Phase I and the first-ever Lassa fever vaccine into Phase II trials. A key player in the COVID-19 response, CEPI also has one of the world’s largest COVID-19 vaccine portfolios and co-led COVAX, which helped to distribute nearly 2 billion doses to 146 nations.
Impact Stories
Latest News
Latest News
CEPI partners with Ethris to increase access to RNA vaccines through spray-dry technique
Funding will support development of spray-dried, thermostable RNA vaccines
Pushing mRNA vaccine development timelines to new speeds
New technology could streamline production of mRNA and improve global access
Groundbreaking study in Rwanda to unlock new insights into Marburg virus immunity
Rwandans who recently recovered from Marburg infection will participate in the study to help unlock clues about the body’s response to the virus.
New CEPI funding to spearhead pandemic preparedness research
The University of Saskatchewan’s Vaccine and Infectious Disease Organization (VIDO) is advancing their broadly protective coronavirus vaccine candidate.
Afrigen to develop human mRNA Rift Valley fever vaccine
CEPI funding will advance the vaccine candidate through preclinical development and Phase I trials.
